NVCR

SEC source: 0001562180-25-004557 · primarydocument.xml · nonDerivative · entry 1

Scannell Timothy J · CIK 0001451533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,233

F1 · security: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.

SEC source: 0001562180-25-004556 · primarydocument.xml · derivative · entry 2

Hung David · CIK 0001310880 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,697

Underlying: Ordinary Shares · 16,697 shares

Expires 2035-06-04

F2 · derivative.exercise_date: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.

SEC source: 0001562180-25-004556 · primarydocument.xml · nonDerivative · entry 1

Hung David · CIK 0001310880 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,410

F1 · security: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.

SEC source: 0001562180-25-004555 · primarydocument.xml · derivative · entry 2

VERNON W ANTHONY · CIK 0001369091 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,697

Underlying: Ordinary Shares · 16,697 shares

Expires 2035-06-04

F2 · derivative.exercise_date: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.

SEC source: 0001562180-25-004555 · primarydocument.xml · nonDerivative · entry 1

VERNON W ANTHONY · CIK 0001369091 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 179,102

F1 · security: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.

SEC source: 0001562180-25-004553 · primarydocument.xml · nonDerivative · entry 1

Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 347,878

F1 · security: Represents restricted share units that are scheduled to vest in equal installments on June 4, 2026 and 2027, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-25-004441 · primarydocument.xml · nonDerivative · entry 1

Stafford Kristin · CIK 0001970438 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,054

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $17.1025 USD to $17.50 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001562180-25-004440 · primarydocument.xml · nonDerivative · entry 1

LEUNG GABRIEL · CIK 0001236183 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,229

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $17.1025 USD to $17.50 USD; the price reported above reflects the weighted average sale price.

F3 · balance_after: Amended total to correct prior mathematical error.

SEC source: 0001562180-25-004438 · primarydocument.xml · nonDerivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,674

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $17.1025 USD to $17.50 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001562180-25-004433 · primarydocument.xml · nonDerivative · entry 1

Scannell Timothy J · CIK 0001451533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,018

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $17.1025 USD to $17.50 USD; the price reported above reflects the weighted average sale price.

F3 · balance_after: Amended total to correct prior mathematical error.

SEC source: 0001562180-25-004431 · primarydocument.xml · nonDerivative · entry 1

HILLEMAN JERYL L · CIK 0001216628 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,591

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $17.1025 USD to $17.50 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001562180-25-004430 · primarydocument.xml · nonDerivative · entry 1

Ocean Allyson J · CIK 0001967326 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,054

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $17.1025 USD to $17.50 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001562180-25-004429 · primarydocument.xml · nonDerivative · entry 1

VERNON W ANTHONY · CIK 0001369091 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 167,887

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $17.1025 USD to $17.50 USD; the price reported above reflects the weighted average sale price.

F3 · balance_after: Amended total to correct prior mathematical error.

SEC source: 0001562180-25-004428 · primarydocument.xml · nonDerivative · entry 1

Hung David · CIK 0001310880 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,195

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $17.1025 USD to $17.50 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001562180-25-004426 · primarydocument.xml · nonDerivative · entry 3

Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 168,452

F3 · price: On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 1,879 shares in multiple trades at prices ranging from $18.78 to $19.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-004426 · primarydocument.xml · nonDerivative · entry 2

Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 170,331

F2 · price: On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 6,600 shares in multiple trades at prices ranging from $17.71 to $18.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-004426 · primarydocument.xml · nonDerivative · entry 1

Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 176,931

F1 · price: On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 21,717 shares in multiple trades at prices ranging from $16.71 to $17.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-003589 · primarydocument.xml · nonDerivative · entry 1

Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,556

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $17.8550 USD to $17.9498 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001562180-25-002157 · primarydocument.xml · derivative · entry 2

Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,499

Underlying: Ordinary Shares · 81,499 shares

Expires 2035-03-03

F2 · derivative.exercise_date: Options to buy 81,499 ordinary shares will vest in equal installments on each of March 4, 2026, 2027, 2028 and 2029, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-25-002157 · primarydocument.xml · nonDerivative · entry 1

Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,148

F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on March 4, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-25-002160 · primarydocument.xml · derivative · entry 2

Weinberg Uri · CIK 0001811030 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,499

Underlying: Ordinary Shares · 81,499 shares

Expires 2035-03-03

F2 · derivative.exercise_date: Options to buy 81,499 ordinary shares will vest in equal installments on each of March 4, 2026, 2027, 2028 and 2029, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-25-002160 · primarydocument.xml · nonDerivative · entry 1

Weinberg Uri · CIK 0001811030 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 221,218

F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on March 4, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-25-002165 · primarydocument.xml · derivative · entry 2

Brackmann Christoph · CIK 0002048634 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,499

Underlying: Ordinary Shares · 81,499 shares

Expires 2035-03-03

F2 · derivative.exercise_date: Options to buy 81,499 ordinary shares will vest in equal installments on each of March 4, 2026, 2027, 2028 and 2029, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-25-002165 · primarydocument.xml · nonDerivative · entry 1

Brackmann Christoph · CIK 0002048634 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,150

F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on March 4, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-25-002163 · primarydocument.xml · derivative · entry 2

Leupin Nicolas · CIK 0002007766 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,499

Underlying: Ordinary Shares · 81,499 shares

Expires 2035-03-03

F2 · derivative.exercise_date: Options to buy 81,499 ordinary shares will vest in equal installments on each of March 4, 2026, 2027, 2028 and 2029, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-25-002163 · primarydocument.xml · nonDerivative · entry 1

Leupin Nicolas · CIK 0002007766 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,108

F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on March 4, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-25-002162 · primarydocument.xml · derivative · entry 2

Ben Arye Barak · CIK 0001917165 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,499

Underlying: Ordinary Shares · 81,499 shares

Expires 2035-03-03

F2 · shares: Options to buy 81,499 ordinary shares will vest in equal installments on each of March 4, 2026, 2027, 2028 and 2029, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-25-002162 · primarydocument.xml · nonDerivative · entry 1

Ben Arye Barak · CIK 0001917165 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 173,696

F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on March 4, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-25-002161 · primarydocument.xml · derivative · entry 2

Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,499

Underlying: Ordinary Shares · 81,499 shares

Expires 2035-03-03

F2 · derivative.exercise_date: Options to buy 81,499 ordinary shares will vest in equal installments on each of March 4, 2026, 2027, 2028 and 2029, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-25-002161 · primarydocument.xml · nonDerivative · entry 1

Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 163,681

F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on March 4, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-25-002159 · primarydocument.xml · derivative · entry 2

Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,499

Underlying: Ordinary Shares · 81,499 shares

Expires 2035-03-03

F2 · shares: Options to buy 81,499 ordinary shares will vest in equal installments on each of March 4, 2026, 2027, 2028 and 2029, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-25-002159 · primarydocument.xml · nonDerivative · entry 1

Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 198,648

F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on March 4, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-25-002156 · primarydocument.xml · derivative · entry 2

Cordova Ashley · CIK 0001822014 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 224,123

Underlying: Ordinary Shares · 224,123 shares

Expires 2035-03-03

F2 · derivative.exercise_date: Options to buy 224,123 ordinary shares will vest in equal installments on each of March 4, 2026, 2027, 2028 and 2029, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-25-002156 · primarydocument.xml · nonDerivative · entry 1

Cordova Ashley · CIK 0001822014 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 355,186

F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on March 4, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-25-001974 · primarydocument.xml · nonDerivative · entry 1

Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,173

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: On the transaction date, the reporting person sold 250 shares in multiple trades at prices ranging from $18.02 to $18.9918. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001977 · primarydocument.xml · nonDerivative · entry 1

Weinberg Uri · CIK 0001811030 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 166,243

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: On the transaction date, the reporting person sold 268 shares in multiple trades at prices ranging from $18.8304 to $18.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001976 · primarydocument.xml · nonDerivative · entry 1

Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,673

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: On the transaction date, the reporting person sold 2,527 shares in multiple trades at prices ranging from $18.02 to $18.9918. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001975 · primarydocument.xml · nonDerivative · entry 1

Cordova Ashley · CIK 0001822014 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 204,005

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: On the transaction date, the reporting person sold 2,053 shares in multiple trades at prices ranging from $18.02 to $18.9918. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001912 · primarydocument.xml · nonDerivative · entry 3

Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,423

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4 · price: On February 28, 2025, the reporting person sold 368 shares in multiple trades at prices ranging from $18.175 to $18.765. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001831 · primarydocument.xml · nonDerivative · entry 3

Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,423

F3 · price: On February 28, 2025, the reporting person sold 368 shares in multiple trades at prices ranging from $18.175 to $18.765. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001917 · primarydocument.xml · nonDerivative · entry 2

Weinberg Uri · CIK 0001811030 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 166,511

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · price: On February 28, 2025, the reporting person sold 311 shares in multiple trades at prices ranging from $18.30 to $18.316. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001917 · primarydocument.xml · nonDerivative · entry 1

Weinberg Uri · CIK 0001811030 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 166,822

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: On February 28, 2025, the reporting person sold 4,326 shares in multiple trades at prices ranging from $18.73 to $18.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001837 · primarydocument.xml · nonDerivative · entry 2

Weinberg Uri · CIK 0001811030 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 166,511

F2 · price: On February 28, 2025, the reporting person sold 311 shares in multiple trades at prices ranging from $18.30 to $18.316. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001837 · primarydocument.xml · nonDerivative · entry 1

Weinberg Uri · CIK 0001811030 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 166,822

F1 · price: On February 27, 2025, the reporting person sold 4,326 shares in multiple trades at prices ranging from $18.73 to $18.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001916 · primarydocument.xml · nonDerivative · entry 3

Cordova Ashley · CIK 0001822014 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 206,058

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4 · price: On February 28, 2025, the reporting person sold 2,341 shares in multiple trades at prices ranging from $18.175 to $18.765. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001915 · primarydocument.xml · nonDerivative · entry 3

Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 146,200

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4 · price: On February 28, 2025, the reporting person sold 2,770 shares in multiple trades at prices ranging from $18.175 to $18.765. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001834 · primarydocument.xml · nonDerivative · entry 3

Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 146,200

F3 · price: On February 28, 2025, the reporting person sold 2,770 shares in multiple trades at prices ranging from $18.175 to $18.765. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001833 · primarydocument.xml · nonDerivative · entry 3

Cordova Ashley · CIK 0001822014 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 206,058

F3 · price: On February 28, 2025, the reporting person sold 2,341 shares in multiple trades at prices ranging from $18.175 to $18.765. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001912 · primarydocument.xml · nonDerivative · entry 2

Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,791

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · price: On February 27, 2025, the reporting person sold 267 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001912 · primarydocument.xml · nonDerivative · entry 1

Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,058

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: On February 27, 2025, the reporting person sold 1,379 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.